Roche to file early for US approval of trastuzumab-DM1
This article was originally published in Scrip
Executive Summary
Roche is planning to file early for US approval this year of its HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of advanced, third-line HER2-positive breast cancer, on the basis of strong response rate data from single-arm Phase II trials.